Clinical and pharmacological properties of XXXX and its use in @entity16 .

@entity1 @entity7124 @entity64 @entity6389 @entity508 @entity16 @entity425 @entity4164 @entity4048 @entity936 @entity1282 @entity9663 @entity158 @entity1736 @entity306
BACKGROUND: IncobotulinumtoxinA ( @entity7124 (  )) is a purified botulinum neurotoxin type A formulation, free from complexing proteins, with proven efficacy and good tolerability for the treatment of neurological conditions such as @entity9663 , @entity6389 ( @entity6389 ), and post- @entity64 @entity508 of the upper limb. This article provides a comprehensive overview of incobotulinumtoxinA based on randomized controlled trials and prospective clinical studies. SUMMARY: IncobotulinumtoxinA provides clinical efficacy in treating @entity9663 , @entity6389 , and upper-limb post- @entity64 @entity508 based on randomized, double-blind, placebo-controlled trials with open-label extension periods (total study duration up to 89 weeks). Adverse events were generally mild or moderate. The most frequent adverse events, probably related to the injections, included @entity1736 and @entity936 in the treatment of @entity9663 , @entity1282 , @entity4048 , and @entity425 in @entity1 with @entity6389 , and injection site @entity158 and @entity425 when used for treating @entity508 . In @entity9663 and @entity6389 , incobotulinumtoxinA was investigated in clinical trials permitting flexible intertreatment intervals based on the individual @entity1 's clinical need; the safety profile of intervals shorter than 12 weeks was comparable to intervals of 12 weeks and longer. There were no cases of newly formed neutralizing antibodies during the Phase III and IV incobotulinumtoxinA trials. Phase III head-to-head trials of incobotulinumtoxinA versus onabotulinumtoxinA for the treatment of @entity9663 and @entity6389 have demonstrated therapeutic equivalence of both formulations. Additional Phase III trials of incobotulinumtoxinA in conditions such as lower-limb @entity508 , @entity508 in @entity1 with @entity306 , and @entity4164 in various @entity16 are ongoing. CONCLUSION: IncobotulinumtoxinA is an effective, well-tolerated botulinum neurotoxin type A formulation. Data from randomized clinical trials and further observational studies are expected to help physicians to optimize treatment by tailoring the choice of formulation, dose, and treatment intervals to the @entity1 's clinical needs.
